AbbVie shares edge higher after positive Phase 3 topline results
AbbVie stock rose in early trading after the company reported positive Phase 3 topline results for its menstrual migraine treatment atogepant (QULIPTA/AQUIPTA) in the LUNA trial. AbbVie also declared a quarterly cash dividend of $1.73 per share.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.